Phase 1, SAD/MAD of Verasone™ Administered by Sinonasal Irrigation in Healthy Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-15

Study Completion Date

2024-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Verasone™ is an aqueous suspension of the combination of two marketed drugs to be dosed by sinonasal irrigation in the treatment of Chronic Rhinosinusitis (CRS). This Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of Verasone versus placebo in healthy normal participants and will evaluate the PK profiles of the Verasone active components administered individually vs in combination.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VVN432 Nasal Spray

NCT07259538

Chronic Rhinosinusitis (CRS)

RECRUITING PHASE1

Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

NCT04930900

Upper Respiratory Tract Infection

COMPLETED PHASE1

Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps

NCT03102190

Sinusitis Nasal Polyps

TERMINATED PHASE1

Blown Nasal Secretion Measurements in Rhinosinusitis: Repeatability and Validity Compared to Nasal Lavage

NCT00292851

Rhinosinusitis

COMPLETED

Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)

NCT04163978

Chronic Sinusitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Single Ascending Dose (SAD), Single Dose Active Components PK Crossover, Multiple Ascending Dose (MAD)

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Double-Blind, Placebo-Controlled

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Verasone

Administered by sinonasal irrigation.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. In good general health based on medical history, physical examination, vital signs, ECG, laboratory parameters, and other relevant tests
2. Able to perform study procedures, including self-administration of sinonasal irrigation of 60 mL in each nostril
3. Able and willing to attend the necessary visits to the study site.

4. Participant met all eligibility criteria for Part A, completed Part A with no major protocol deviations, and all Part A safety and PK assessments were completed, in the opinion of the PI.
5. Participant did not experience local toxicity AEs or anterior rhinoscopy findings during Part A.

Exclusion Criteria

1. History of allergy, hypersensitivity, or contraindication to corticosteroids or calcium channel blockers.
2. History of severe allergic or anaphylactic reactions or sensitivity to the IP or its constituents.
3. Any clinical obstruction of the nasal cavities that would reduce access for topical irrigations
4. Nasal candidiasis, nasal mucosal ulceration, thinning or eroded nasal septum, or nasal septum perforation.
5. History or clinical evidence of CRS, fungal rhinosinusitis, or rhinitis medicamentosa at any time, or any active allergic rhinitis, acute sinusitis, or upper respiratory infection within 4 weeks prior to Screening.
6. Ongoing nasal congestion at Screening or Day -1 (Nasal Congestion Score \> 0).
7. Inability to have anterior rhinoscopy nasal examination (Parts A and B only) or endoscopic nasal cavity examination (Part C only).
8. More than 1 episode of epistaxis.
9. History of or planned sinus or intranasal surgery.
10. Use of immunomodulating drugs, except glucocorticoids, within 90 days prior to Screening or intent to use these drugs during the study.
11. Exposure to any glucocorticoid treatment via any route (nasal, topical, inhaled, oral, intravenous, etc.) within 1 month prior to Screening.
12. Received biologic therapy/systemic immunosuppressant to treat inflammatory or autoimmune disease.
13. Oral steroid-dependent or monoclonal antibody-dependent (eg, omalizumab, mepolizumab, dupilumab) condition.
14. Use of potent cytochrome P450 3A4 (CYP3A4) inhibitor(s) or inducer(s) within 14 days prior to Screening.
15. Known history of HPA axial dysfunction, or previous pituitary or adrenal surgery.
16. History or diagnosis of eustachian tube dysfunction, recurrent otitis media.
17. Any history or ongoing clinically significant cardiac disease.
18. Abnormal vital signs or ECG findings.
19. History or current diagnosis of any form of glaucoma or ocular hypertension.
20. A history of cancer, HIV, or other immunodeficiency, or immune system-mediated disorder.
21. History of insulin-dependent diabetes mellitus.
22. History of any clinically significant hepatic or renal disease.
23. Clinically significant abnormal laboratory parameters at Screening.
24. Any underlying physical or psychological medical condition.
25. A recent clinically significant history of drug or alcohol use, abuse, or dependence.
26. Positive screen for drugs of abuse or alcohol at Screening or Day -1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes